Edwards Lifesciences (EW) Tops Q4 EPS by 3c, Offers Q1 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Northland Capital Remains Positive on Edwards Lifesciences (EW) Long-Term Outlook
February 2, 2017 12:50 PM ESTNorthland Capital Markets analyst Suraj Kalia is sticking with her Outperform rating and $105 price target on Edwards Lifesciences (NYSE: EW) even though the company is hard time meeting lofty Street expectations.
Kalia commented, "Q4-16 revs @ $768M > consensus @ $758M & our estimate @ $763M. GAAP EPS @ $0.73 > our estimate @ $0.71 &... More
Leerink Partners Downgrades Edwards Lifesciences (EW) to Market Perform
February 2, 2017 9:34 AM ESTLeerink Partners downgraded Edwards Lifesciences (NYSE: EW) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $98.02 yesterday.
... More


